| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 67.3 | 58.4 | 72.8 |
| Other income | 0.1 | 0.2 | 0.5 |
| Total income | 67.4 | 58.6 | 73.2 |
| Profit before exceptional items & tax | -13.3 | -9.8 | 1.6 |
| Profit before tax | -13.3 | -9.8 | 1.6 |
| Net profit | -13.4 | -9.8 | 0.1 |
| Operating margin | -19.7% | -16.7% | 2.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -7.60% |
|---|
BSE results filing, NSE: MANGALAM. Figures extracted from the filing.
Mangalam Drugs and Organics Ltd: key numbers
- Share price
- ₹31.83
- Market cap
- ₹50.38 Cr
- Revenue (annual)
- ₹232.1 Cr
- Net profit (annual)
- ₹-44.40 Cr
- P/E (TTM)
- -1.3×Sector 50.4×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mangalam Drugs and Organics Ltd
All →Mangalam Drugs and Organics Other Announcement
Mangalam Drugs and Organics Limited announced the appointment of new Statutory and Secretarial Auditors following the tenure completion of the previous Statutory Auditor.
Mangalam Drugs and Organics Management Change
Manglam Drugs and Organics Ltd. has appointed M/s S.N. Nanda & Co. as Statutory Auditor and M/s L.N. Joshi & Co. as Secretarial Auditor.
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs and Organics Ltd held its 53rd Annual General Meeting on September 23, 2026. The meeting transacted standard business items including financial statement adoption and auditor appointments.
Mangalam Drugs and Organics Legal & Regulatory
Mangalam Drugs and Organics reported a bank default amounting to Rs. 15.57 Crore. The company has submitted a restructuring proposal to the banks for resolution.
- Value
- ₹15.57 Cr
Mangalam Drugs and Organics Debt & Borrowing: ₹15.57 Cr
Mangalam Drugs disclosed a default on loan obligations to Bank of Maharashtra and Bank of Baroda, totaling ₹15.57 Crore in overdue amounts.
- Value
- ₹15.57 Cr
Mangalam Drugs and Organics Management Change
Mangalam Drugs and Organics Limited has appointed Mr. Prabhakar Raghunath Zavar as a Non-Executive Independent Director, effective September 15, 2026.